ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update

Core Insights - ADMA Biologics, Inc. reported preliminary unaudited total revenue for FY 2024 between $417 million and$425 million, exceeding previous guidance of $415 million [1] - The company’s total cash holdings at year-end 2024 grew to over$100 million, reflecting a net cash surplus despite discharging $30 million of debt during Q4 2024 [1] - ADMA anticipates generating over$1 billion in total annual revenue prior to 2030, more than doubling the current 2025 revenue forecast [1][7] Financial Performance - FY 2025 and 2026 total revenue guidance is expected to exceed $485 million and$600 million, respectively [3][7] - FY 2025 and 2026 net income is expected to exceed $170 million and$230 million, respectively [3][7] - FY 2025 and 2026 adjusted EBITDA is expected to exceed $220 million and$300 million, respectively [3][7] Business Updates - Newly executed long-term high-titer plasma supply contracts are expected to support ASCENIV revenue growth through the late 2030s [2][7] - A Prior Approval Supplement (PAS) has been submitted to the FDA for an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025 [2][7] - The innovative process is expected to increase Immunoglobulin (IG) yields by approximately 20%, driving revenue and earnings increases starting later in 2025 [2][7] Strategic Positioning - ADMA has solidified high-titer plasma supply on a long-term basis, increasing access to raw material plasma from approximately 250 collection centers, a five-fold increase in total collection capacity [7] - The company is focused on optimizing its balance sheet, having generated approximately $45 million in operating cash flow in Q4 2024, leading to a net cash surplus relative to its outstanding debt [7] - ADMA is leveraging its robust intellectual property estate and innovative R&D engine, with potential upside from its lead R&D pipeline program, SG-001, targeting S. pneumonia [7]